Skip to content 
Recently, at the 2025 Jiangsu Industry-University-Research Cooperation and Connection Conference theme Conference, the Great Wall Enterprise Strategy Research Institute released for the first time the 2025 China Science and Technology Innovation Future Star Enterprise Research Report. The report selected a total of 80 early-stage start-up enterprises with cutting-edge and disruptive technological innovation capabilities, among which 21 are from Jiangsu Province, tying with Beijing for the top spot in the country. A total of 7 enterprises from Nanjing were selected. Among them, Nanjing Jisheng Aoma Biomedical Co., LTD., an enterprise in the Nanjing Biomedical Valley Park of Jiangbei New Area, successfully made the list with its outstanding innovation capabilities, becoming a shining “future star” in the park.
“Future Star of Science and Technology Innovation
Based on years of research on high-growth enterprises such as gazelles and unicorns, the Great Wall Enterprise Strategy Research Institute proposed the concept of “Future Stars of Science and Technology Innovation” for the first time this year. “Future Stars of Science and Technology Innovation” enterprises refer to technology startups that possess cutting-edge and disruptive technological innovation capabilities and demonstrate technological leadership, commercialization potential, and high-value potential in their early stages of entrepreneurship. This research institute has gathered nearly a hundred domestic technology enterprise investment and incubation institutions, organized expert reviews, and compiled the country’s first list of “Future Stars of Science and Technology Innovation” enterprises.
Wu Wensheng, director of the Great Wall Enterprise Strategy Research Institute, introduced that the “Future Stars of Science and Technology Innovation” enterprises share distinct commonalities. For instance, they focus on the key directions of the national strategic layout, and through the exploration of cutting-edge technologies or disruptive technological innovations, achieve breakthroughs from “0 to 1” and solve the “bottleneck” problems. Most of the 80 enterprises are in the seed stage or start-up stage, demonstrating high value potential. The founding team generally has a compound background of “technical experts + entrepreneurs”. According to statistics, all 80 enterprises have received financing, with a cumulative financing amount exceeding 10 billion yuan and an average financing amount of 150 million yuan per enterprise.
Jisheng Aoma was founded in 2021 and is a clinical-stage biopharmaceutical company. Its core team comes from renowned global biopharmaceutical enterprises. The company focuses on the immunotherapy of respiratory diseases. Through a differentiated drug research and development path, it has established multiple innovative drug research and development platforms, including nucleic acid drug research and development, respiratory preparations and delivery, and innate immune antibody research and development. From these, it has obtained several candidate drugs with global intellectual property rights and wide clinical applications. At present, there are six pipelines. Among them, the immunomodulatory small nucleic acid product IAMA-001 nasal spray has completed the Phase I clinical trial, demonstrating excellent safety and tolerability, and is about to enter the Phase II clinical trial.
It is worth mentioning that at the 2025 Jiangsu Industry-University-Research Cooperation and Connection Conference theme Conference, many enterprises in the park also brought a series of innovative achievements:
Xiansheng Pharmaceutical – Edaravone Dexcamneol Sublingual Tablets (Xianbixin ® Sublingual Tablets) : The world’s first brain-protective drug to be recognized as a “Breakthrough Therapy” by the U.S. Food and Drug Administration (FDA).
Reindeer Bio – Ikiolencel Injection (Fukesu ®) : The world’s first fully human CAR-T cell drug targeting BCMA to be marketed.
Shihe Gene – “Shihe No.1 ®” Non-Small Cell Lung Cancer TMB Detection Kit: It is the first and only NGS large Panel kit and the first TMB detection kit in China, and an innovative medical device of NMPA.
Weican Medical – Implantable Drug Delivery devices and their Accessories: An innovative solution designed for patients undergoing long-term intravenous treatment.
The selection of Jisheng Aoma this time and the simultaneous appearance of many enterprises in the park are another example of the innovative strength of Nanjing Biomedical Valley. As a key development center for the life and health industry in Nanjing, the Medicine Valley continuously optimizes its innovation ecosystem and accelerates the aggregation of the world’s top resources. At present, the park has gathered over 1,300 enterprises in the field of life and health, with a total of 405 listed drugs, including 6 first-class new drugs, and more than 200 first-class new drugs under research and development.
In the future, the park will accelerate the construction of a four-in-one, full-chain integrated biopharmaceutical industry innovation ecosystem featuring “learning, research, production and application”, cultivate and expand innovation entities, empower more enterprises in the park to produce more innovative drugs with international competitiveness, and accelerate the creation of a leading domestic biopharmaceutical innovation and industrialization highland.
